The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40%...
Guardado en:
Autor principal: | Radcliffe NM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5aef8b2261c0435b9664d2c60ef48a3e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Nicholas P Bell, et al.
Publicado: (2010) -
Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
por: Jaime Pablo Kelly Rigollet, et al.
Publicado: (2011) -
Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa K, et al.
Publicado: (2014) -
Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão MLS, et al.
Publicado: (2014) -
Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy
por: Norbert Pfeiffer, et al.
Publicado: (2010)